Efficacy of androgen deprivation therapy and the role of oxidative stress

被引：6
作者：
Price, D. K. [1 ]
机构：
[1] Natl Canc Inst, Natl Inst Hlth, Genitourinary Malignancies Branch, Bethesda, MD USA
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷 / 03期
基金：
美国国家卫生研究院;
关键词：
RESISTANT PROSTATE-CANCER; INCREASED SURVIVAL; MITOXANTRONE; PREDNISONE;
D O I：
10.1093/annonc/mdx001
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：451 / 453
页数：4
相关论文
共 50 条
  • [31] The hypothalamic-pituitary-gonadal axis and prostate cancer: implications for androgen deprivation therapy
    Kluth, Luis A.
    Shariat, Shahrokh F.
    Kratzik, Christian
    Tagawa, Scott
    Sonpavde, Guru
    Rieken, Malte
    Scherr, Douglas S.
    Pummer, Karl
    WORLD JOURNAL OF UROLOGY, 2014, 32 (03) : 669 - 676
  • [32] Improving intermittent androgen deprivation therapy: lessons learned from basic and translational research
    Parikh, Rahul A.
    Pascal, Laura E.
    Davies, Benjamin J.
    Wang, Zhou
    ASIAN JOURNAL OF ANDROLOGY, 2014, 16 (04) : 505 - 510
  • [33] Docetaxel plus androgen deprivation withdrawal may restore sensitivity to luteinizing hormone-releasing hormone analog therapy in castration-resistant prostate cancer patients
    Bedussi, Francesca
    Valcamonico, Francesca
    Mosca, Alessandra
    Sigala, Sandra
    Ferrari, Laura
    Terrone, Carlo
    Dalla Volta, Alberto
    Marchioro, Giansilvio
    Ferrari, Vittorio
    Alabiso, Oscar
    Memo, Maurizio
    Berruti, Alfredo
    ENDOCRINE, 2016, 54 (03) : 830 - 833
  • [34] mCRPC Patients Receiving 225Ac-PSMA-617 Therapy in the Post-Androgen Deprivation Therapy Setting: Response to Treatment and Survival Analysis
    Sathekge, Mike
    Bruchertseifer, Frank
    Vorster, Mariza
    Lawal, Ismaheel O.
    Knoesen, Otto
    Mahapane, Johncy
    Davis, Cindy
    Mdlophane, Amanda
    Maes, Alex
    Mokoala, Kgomotso
    Mathabe, Kgomotso
    Van de Wiele, Christophe
    Morgenstern, Alfred
    JOURNAL OF NUCLEAR MEDICINE, 2022, 63 (10) : 1496 - 1502
  • [35] Validity and Future of Primary Androgen Deprivation Therapy in Prostate Cancer. Integration in the Era of New Agents Targeting the Androgen Receptor
    Carballido, Joaquin
    ARCHIVOS ESPANOLES DE UROLOGIA, 2023, 76 (01): : 1 - 28
  • [36] Androgen deprivation treatment in prostate cancer
    Thomas, Benjamin C.
    Neal, David E.
    BMJ-BRITISH MEDICAL JOURNAL, 2013, 346
  • [37] Radiation and Androgen Deprivation Therapy With or Without Docetaxel in the Management of Nonmetastatic Unfavorable-Risk Prostate Cancer: A Prospective Randomized Trial
    D'Amico, Anthony, V
    Xie, Wanling
    McMahon, Elizabeth
    Loffredo, Marian
    Medeiros, Shana
    Joseph, David
    Denham, Jim
    Kumar, Parvesh
    Bubley, Glenn
    Sullivan, Molly
    Hellwig, Richard
    Vera, Juan Carlos
    Freter, Rolf
    Baker, W. Jeffrey
    Wong, Jeffrey Y.
    Renshaw, Andrew A.
    Kantoff, Philip W.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (26) : 2938 - +
  • [38] First Line Androgen Deprivation Therapy Duration Is Associated with the Efficacy of Abiraterone Acetate Treated Metastatic Castration-Resistant Prostate Cancer after Docetaxel
    Li, Jian-Ri
    Wang, Shian-Shiang
    Yang, Cheng-Kuang
    Chen, Chuan-Su
    Ho, Hao-Chung
    Chiu, Kun-Yuan
    Hung, Chi-Feng
    Cheng, Chen-Li
    Yang, Chi-Rei
    Chen, Cheng-Che
    Wang, Shu-Chi
    Lin, Chia-Yen
    Ou, Yen-Chuan
    FRONTIERS IN PHARMACOLOGY, 2017, 8
  • [39] A phase II trial of androgen deprivation therapy (ADT) plus chemotherapy as initial treatment for local failures or advanced prostate cancer
    Amato, Robert
    Stepankiw, Mika
    Gonzales, Patricia
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (06) : 1629 - 1634
  • [40] Evaluating Intermittent Androgen-Deprivation Therapy Phase III Clinical Trials: The Devil Is in the Details
    Hussain, Maha
    Tangen, Catherine
    Higano, Celestia
    Vogelzang, Nicholas
    Thompson, Ian
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (03) : 280 - U147
12345